Physician profile
Milan Dodig
NPI 1730123514
$26,505.04
in general payments reported to CMS, 2019-2025
56 companies · $4,752 in 2025
The $4,752 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,995 · 2020: $2,590 · 2021: $3,852 · 2022: $4,611 · 2023: $3,431 · 2024: $4,275 · 2025: $4,752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,334.26 |
| Education | $123.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,038.36 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,162.35 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $3,020.42 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,541.91 | 2019-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $1,002.49 | 2019-2025 | Livdelzi, Epclusa |
| Ironwood Pharmaceuticals, INC | $806.11 | 2019-2024 | Linzess |
| Redhill Biopharma INC. | $719.60 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $654.30 | 2019-2025 | Ocaliva |
| Daiichi Sankyo INC. | $653.39 | 2019-2025 | Injectafer |
| Genzyme Corporation | $632.92 | 2022-2025 | |
| Pfizer INC. | $591.30 | 2019-2025 | |
| Qol Medical, LLC | $579.45 | 2019-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $565.04 | 2022-2025 | Ibsrela |
| Celgene Corporation | $496.81 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $448.43 | 2021-2023 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $347.60 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $344.73 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $334.11 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $274.16 | 2019-2024 | Dificid |
| Aimmune Therapeutics, INC. | $254.02 | 2024-2025 | Vowst, Zenpep |
| Ipsen Biopharmaceuticals, INC | $251.10 | 2024-2025 | Iqirvo, Bylvay |
| Novo Nordisk INC | $230.32 | 2020-2025 | Wegovy |
| Evoke Pharma, INC. | $189.93 | 2022-2025 | |
| Eisai INC. | $183.45 | 2019 | |
| Medtronic, INC. | $174.94 | 2023-2025 | Interstim |
| Celltrion USA INC. | $167.82 | 2024-2025 | Vegzelma, Zymfentra |
| Ferring Pharmaceuticals INC. | $164.30 | 2019-2024 | Rebyota |
| Dova Pharmaceuticals | $141.80 | 2019 | |
| Allergan, INC. | $134.60 | 2019 | |
| Janssen Scientific Affairs, LLC | $122.26 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $120.44 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $108.64 | 2022-2023 | Dupixent |
| Shionogi INC | $101.08 | 2019-2020 | |
| Ucb, INC. | $87.73 | 2019-2020 | |
| Amgen INC. | $73.85 | 2023-2025 | Amjevita, Uplizna |
| Shire North American Group INC | $73.57 | 2019 | |
| Vivus LLC | $69.02 | 2021-2025 | Qsymia |
| Alfasigma USA, INC. | $65.95 | 2020-2021 | |
| Fresenius Kabi USA, LLC | $65.55 | 2023 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.52 | 2024 | Cyltezo |
| Concordia Pharmaceuticals INC. | $61.65 | 2019 | |
| Organon LLC | $51.83 | 2023-2024 | Hadlima |
| Braintree Laboratories, INC. | $47.32 | 2021-2024 | Suflave, Sutab |
| Alexion Pharmaceuticals, INC. | $40.15 | 2019 | |
| Meridian Bioscience INC. | $37.76 | 2024 | |
| Mylan Institutional INC. | $35.35 | 2023 | Hulio |
| Exact Sciences Corporation | $34.62 | 2023-2025 | The Cologuard Plus Collection Kit |
| Mirum Pharmaceuticals, INC. | $26.04 | 2023 | Livmarli |
| Axonics, INC. | $20.01 | 2021 | |
| Biocon Biologics INC | $18.51 | 2024 | Hulio |
| Horizon Therapeutics Plc | $14.37 | 2022 | |
| Romark Laboratories, Lc | $13.80 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $13.47 | 2020 | |
| Conmed Corporation | $13.32 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 | |
| Mauna Kea Technologies, INC. | $8.99 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milan Dodig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.